Table 3.
Percentage of patients in each stratum taking a particular drug class
| ACEI | Thiazide | CCB | ARB | Beta blocker | Alpha blocker | Nonthiazide diuretics | Other | Total | |
|---|---|---|---|---|---|---|---|---|---|
| Total | 28.5% | 24.2% | 21.1% | 21.5% | 18.7% | 0.6% | 3.7% | 2.4% | 120.7% |
| Age | |||||||||
| Age < 60 | 33.9% | 27.2% | 20.2% | 22.7% | 16.7% | 0.3% | 3.2% | 2.5% | 126.7% |
| Age ≥ 60 | 26.5% | 23.5% | 22.8% | 21.8% | 20.9% | 0.8% | 4.2% | 2.5% | 123.0% |
| Gender | |||||||||
| Female | 26.0% | 25.5% | 20.9% | 21.7% | 20.5% | 0.4% | 4.6% | 2.9% | 122.5% |
| Male | 31.9% | 23.7% | 22.1% | 22.0% | 17.5% | 0.8% | 3.0% | 2.0% | 122.9% |
| Race | |||||||||
| White | 29.6% | 23.4% | 19.6% | 21.2% | 19.9% | 0.5% | 3.7% | 2.1% | 120.0% |
| Black | 24.3% | 27.8% | 27.4% | 19.8% | 15.5% | 0.7% | 4.7% | 4.1% | 124.2% |
| Hispanic | 30.5% | 27.6% | 16.5% | 22.3% | 16.8% | 1.2% | 2.0% | 2.6% | 119.6% |
| Asian | 23.9% | 19.9% | 25.2% | 29.5% | 17.9% | 0.4% | 2.5% | 1.9% | 121.2% |
| Other/unspecified | 31.3% | 19.2% | 20.4% | 24.2% | 17.7% | 0.5% | 2.9% | 1.1% | 117.3% |
| Insurance | |||||||||
| 3rd party and PPO | 29.7% | 27.5% | 19.9% | 24.4% | 17.2% | 0.5% | 3.6% | 2.1% | 124.9% |
| HMO | 30.6% | 24.5% | 20.3% | 23.1% | 17.1% | 0.7% | 3.1% | 1.4% | 120.8% |
| Medicare | 25.2% | 21.3% | 22.9% | 20.6% | 21.0% | 0.6% | 4.2% | 2.9% | 118.6% |
| Medicaid | 32.4% | 22.9% | 20.8% | 12.4% | 16.8% | 0.4% | 3.9% | 4.6% | 114.1% |
| Other | 31.6% | 25.1% | 19.9% | 16.3% | 19.0% | 0.6% | 3.0% | 3.0% | 118.6% |
| Old vs. new prescription | |||||||||
| Continued therapy | 31.1% | 26.1% | 22.7% | 22.8% | 20.5% | 0.5% | 4.0% | 2.2% | 129.9% |
| New therapy | 27.3% | 25.0% | 22.5% | 24.0% | 17.8% | 1.2% | 4.1% | 4.7% | 126.6% |
| Prescriber specialty | |||||||||
| Primary carea | 29.4% | 25.3% | 21.1% | 21.9% | 17.6% | 0.5% | 3.9% | 2.0% | 121.7% |
| Cardiology | 20.4% | 18.0% | 23.1% | 22.1% | 26.1% | 0.9% | 3.7% | 2.9% | 117.2% |
| Other | 29.2% | 23.1% | 20.0% | 19.1% | 19.2% | 0.5% | 2.9% | 4.5% | 118.4% |
| Prescriber region | |||||||||
| East | 24.8% | 23.9% | 22.9% | 24.6% | 19.9% | 0.4% | 5.9% | 2.2% | 124.5% |
| Midwest | 32.5% | 25.8% | 19.2% | 17.7% | 19.4% | 0.7% | 7.1% | 2.0% | 124.4% |
| South | 27.9% | 24.4% | 22.1% | 21.8% | 18.6% | 0.7% | 9.3% | 2.9% | 127.6% |
| West | 29.9% | 22.4% | 19.1% | 20.9% | 16.7% | 0.5% | 7.1% | 2.4% | 119.0% |
| SBP | |||||||||
| SBP < 130a | 31.1% | 25.1% | 20.0% | 21.1% | 20.4% | 0.3% | 3.8% | 2.0% | 123.9% |
| SBP 130–139a | 29.7% | 27.8% | 23.1% | 22.3% | 17.2% | 0.4% | 4.3% | 3.0% | 127.8% |
| SBP 140–149a | 27.7% | 24.7% | 23.7% | 22.5% | 17.8% | 1.0% | 4.0% | 3.1% | 124.5% |
| SBP 150–159a | 25.6% | 25.4% | 24.9% | 23.0% | 17.9% | 0.6% | 2.4% | 5.3% | 125.2% |
| SBP ≥ 160a | 25.4% | 26.0% | 26.0% | 20.5% | 20.6% | 0.8% | 3.2% | 9.4% | 131.8% |
Abbreviations: ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; CCB, calcium-channel blockers; SBP, systolic blood pressure.
aPrimary care includes family practice, general practice, internal medicine, geriatrics.
Source: QuintilesIMS, NDTI, 2014.